



# Adult ORH Pharmacy Antimicrobial Dosing Guideline Chart (1/21/07)

	CrCl (ml/min)	≥ 40	39 - 20	< 20	HD	CRRT		
<b>Piperacillin/Tazobactam (Zosyn)</b>	<i>Pseudomonas</i> or serious infection	4.5g Q6H	3.375g Q6H	2.25g Q6H	2.25g Q6H	3.375g Q6H		
<b>Piperacillin/Tazobactam (Zosyn)</b>	Other infections	3.375g Q6H	2.25g IV Q6H	2.25g Q8H	2.25g Q8H	2.25g Q6H		

	Drug	Non-Obese Dosing Weight	Morbid Obesity *
<b>Antibacterials</b>	Amikacin (Amikin)	ABW	Adjusted BW (see aminoglycoside protocol)
	TMP/SMX (Bactrim)	ABW	ABW
	Daptomycin (Cubicin)	ABW	ABW
	Gentamicin (Garamycin)	ABW	Adjusted BW (see aminoglycoside protocol)
	Dalfo/Quinu (Synercid)	ABW	ABW
	Tobramycin (Nebcin/Tobi)	ABW	Adjusted BW (see aminoglycoside protocol)
	Vancomycin (Vancocin)	ABW	ABW
	Colistin (Coly-Mycin)	IBW	IBW
<b>Antifungals</b>	Amphotericin B (Fungizone)	IBW	IBW
	Fluconazole (Diflucan)	ABW	ABW
	Voriconazole (Vfend)	ABW	ABW
<b>Antivirals</b>	Acyclovir (Zovirax)	IBW	IBW
	Ganciclovir (Cytovene)	ABW	ABW

Drugs that do not require renal dosing
Amphotericin B (Fungizone)
Anidulafungin (Eraxis)
Azithromycin (Zithromax)
Caspofungin (Cancidas)
Clindamycin (Cleocin)
Dalfopristin/Quinupristin (Synercid)
Doxycycline (Vibramycin)
Ertapenem (Invanz)
Linezolid (Zyvox)
Lipid Complex Ampho B (Abelcet)
Liposomal Ampho B (Ambisome)
Metronidazole (Flagyl)
Moxifloxacin (Avelox)
Nafcillin (Nafcil)
Oxacillin (Bactocill)
Rifampin (Rifadin)
Tigecycline (Tygacil)

\*Patients with ABW > 150 kg may warrant a discussion with the on-call/satellite mentor clinical pharmacist

# Adult ORH Pharmacy Antimicrobial Dosing Guideline Chart (1/21/07)

- 1) Trotman RL, Williamson JC, Shoemaker DM, et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. *CID* 2005;41:1159-66.
- 2) Klasco RK (Ed): DRUGDEX® System. Thomson Micromedex, Greenwood Village, Colorado (Edition expires 9/2006)].
- 3) Lexi-Comp, Inc. (Lexi-Drugs™). Lexi-Comp, Inc.; September 19, 2006.
- 4) Scheetz MH, Hurt KM, Noskin GA, et al. Applying antimicrobial Pharmacodynamics to resistant gram-negative pathogens. *Am J Health-Syst Pharm* 2006;63:1346-59.
- 5) Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on  $\beta$ -lactam antibiotics. *Pharmacotherapy* 2006;26(9):1320-32.
- 6) Tam VH, Adams S, LaRocco MT, et al. An integrated pharmacoeconomic approach to antimicrobial formulary decision-making. *Am J Health-Syst Pharm* 2006;63:735-9.
- 7) Cappelletty D. Evaluation of several dosing regimens of cefepime, with various simulations of renal function, against clinical isolates of *Pseudomonas aeruginosa* in a pharmacodynamic infection model. *AAC* 1999;43(1):129-33.
- 8) ATS/IDSA Committee. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med* 2005;171:388-416.
- 9) Yagasaki K, Gando S, Matsuda N, et al. Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration. *Intensive Care Med* 2003;29:1844-8.